search
Back to results

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Primary Purpose

Follicular Lymphoma

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Bortezomib
Bortezomib
Sponsored by
Lymphoma Study Association
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Follicular Lymphoma focused on measuring follicular lymphoma, bortezomib, relapse

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female subject 18 years or older. Initial diagnosis of follicular B-cell lymphoma (CD20+) (grades 1, 2, and 3 based on the World Health Organization 1997 classification), in first or subsequent relapse or progression after prior anti-neoplastic treatment including previous rituximab treatment. Relapse or progression since previous anti-neoplastic therapy must be documented by new lesions or objective evidence of progression of existing lesions. At least 1 measurable lymph node mass that is >1.5 cm in 2 perpendicular dimensions, and has not been previously irradiated or has grown since previous irradiation. No active central nervous system (CNS) lymphoma Karnofsky Performance Status (KPS) >50% (Eastern Cooperative Oncology Group [ECOG] 0-2) The following laboratory values at screening, unless abnormalities are related to the lymphoma: Absolute neutrophil count (ANC) >1000 cells/dL; Platelets >50,000 cells/dL; Aspartate transaminase (AST) <3 x upper limit of normal (ULN); Alanine transaminase (ALT) <3 x ULN; Total bilirubin <2 x ULN; Creatinine level <150 µmol/L Toxic effects of previous therapy or surgery resolved to Grade 2 or better. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Women are neither breast feeding nor pregnant for the duration of the study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Male subject agrees to use an acceptable method of contraception for the duration of the study. Voluntary signed informed consent before performance of any study-related procedure not part of normal medical care. Patient with minimum life expectancy of 3 months. Exclusion Criteria: Any other type of lymphoma. Previous treatment with Velcade™. Anti-neoplastic or experimental or radiation therapy within 3 weeks before Day 1 of Cycle 1. Major surgery within 2 weeks before Day 1 of Cycle 1. Rituximab, alemtuzumab (Mabcampath®), or other unconjugated therapeutic antibody within 10 weeks before Day 1 of Cycle 1. Nitrosoureas within 6 weeks before Day 1 of Cycle 1. Radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin™), or tositumomab (Bexxar®) within 10 weeks before Day 1 of Cycle 1. Peripheral neuropathy or neuropathic pain of Grade 3 or worse. History of allergic reaction attributable to compounds containing boron or mannitol. Diagnosed or treated for a malignancy other than non-Hodgkin's lymphoma (NHL) within 5 years before Day 1 of Cycle 1, with the exception of complete resection of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy. Active systemic infection requiring treatment. Previously known HIV positive serology. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Concurrent treatment with another investigational agent. Adult patient under guardian.

Sites / Locations

  • Groupe d'Etude des Lymphomes de l'adulte
  • Service d'Hématologie - Centre Hospitalier Lyon-Sud
  • Centre Henri Becquerel
  • Institut Gustave Roussy

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

A

B

Arm Description

Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,

Outcomes

Primary Outcome Measures

To determine the response rate to Velcade™ as a single agent

Secondary Outcome Measures

To determine the overall complete response (CR) rate (CR + complete response unconfirmed [CRu])
To determine time to progression (TTP)
To determine overall survival
To determine duration of response
To determine the time to best response
To evaluate the safety and tolerability of Velcade™
To evaluate the effects of Velcade™ given biweekly at 1.5 mg/m2 versus 1.6 mg/m2 weekly

Full Information

First Posted
August 26, 2005
Last Updated
October 22, 2010
Sponsor
Lymphoma Study Association
Collaborators
Janssen-Cilag International NV
search

1. Study Identification

Unique Protocol Identification Number
NCT00136591
Brief Title
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Official Title
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2010
Overall Recruitment Status
Terminated
Why Stopped
An arm closed due to lack of efficacy
Study Start Date
September 2005 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Lymphoma Study Association
Collaborators
Janssen-Cilag International NV

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, randomized, sequential, international, multicentric, 2-arm, non-comparative, open-label, 2-stage clinical study to determine disease response rates to Velcade™ therapy in subjects who have relapsed or refractory follicular B-cell lymphoma. Qualitative comparisons of the 2 treatment arms based on safety, efficacy and dosing convenience will be made in order to recommend a dose schedule for further clinical study.
Detailed Description
This is a prospective, randomized, sequential, international, multicentric, 2-arm, non-comparative, open-label, 2-stage clinical study to determine disease response rates therapy of Velcade™ in subjects who have relapsed or refractory follicular B-cell lymphoma (FLL). Qualitative comparisons of the 2 treatment arms based on safety, efficacy and dosing convenience will be made in order to recommend a dose schedule for further clinical study. It is anticipated that approximatively 120 subjects will be enrolled to achieve the required 110 evaluable subjects, 55 in each treatment arm. Patients who receive any amount of Velcade™ are evaluable. Subjects not evaluable for response will be replaced. A central randomization will be used in this study. Subjects will be randomized and stratified with factors for prior therapies (1 or 2 versus > 2) and time to progression (TPP) for the last given anti-neoplastic therapy (≤ 12 months versus > 12 months). The eligible subjects will be randomized to either Treatment Arm A or Treatment Arm B in a 1:1 ratio: Subjects randomized to Treatment Arm A will receive 1.5 mg/m² Velcade™ administered biweekly on Days 1, 4, 8, and 11 of a 21-day cycle. Patients will receive 8 cycles. The dose of Velcade™ received in schedule A will be 48 mg/m² over 24 weeks. Subjects randomized to Treatment Arm B will receive 1.6 mg/m² Velcade™ administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle. Patients will receive 6 cycles. The dose of Velcade™ received in schedule B will be 38.4 mg/m² over 30 weeks. Two additional cycles may be administered if the patient shows improvement to PR after 8 or 6 cycles for arm A or B, respectively. Study drug dose and schedule reduction for toxicity will be allowed during the study. A two stage interim analysis will be conducted in each treatment arm to determine whether either of the 2 treatments lacks sufficient efficacy. The final analysis will be conducted when all subjects have had the opportunity to complete the 30 day post-treatment evaluation visit. All data from all visits up until this point will be used in the final analysis, including data from any follow-up visits that have occurred. Patients will be recruited approximately over 2 years and followed until all data are available for final analysis. The total duration of the study is expected to be 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Follicular Lymphoma
Keywords
follicular lymphoma, bortezomib, relapse

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
Arm Title
B
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Bortezomib
Intervention Description
Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
Intervention Type
Drug
Intervention Name(s)
Bortezomib
Intervention Description
Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
Primary Outcome Measure Information:
Title
To determine the response rate to Velcade™ as a single agent
Time Frame
End of treatment
Secondary Outcome Measure Information:
Title
To determine the overall complete response (CR) rate (CR + complete response unconfirmed [CRu])
Time Frame
End of treatment
Title
To determine time to progression (TTP)
Time Frame
End of study
Title
To determine overall survival
Time Frame
End of study
Title
To determine duration of response
Time Frame
End of study
Title
To determine the time to best response
Time Frame
End of study
Title
To evaluate the safety and tolerability of Velcade™
Time Frame
End of study
Title
To evaluate the effects of Velcade™ given biweekly at 1.5 mg/m2 versus 1.6 mg/m2 weekly
Time Frame
End of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subject 18 years or older. Initial diagnosis of follicular B-cell lymphoma (CD20+) (grades 1, 2, and 3 based on the World Health Organization 1997 classification), in first or subsequent relapse or progression after prior anti-neoplastic treatment including previous rituximab treatment. Relapse or progression since previous anti-neoplastic therapy must be documented by new lesions or objective evidence of progression of existing lesions. At least 1 measurable lymph node mass that is >1.5 cm in 2 perpendicular dimensions, and has not been previously irradiated or has grown since previous irradiation. No active central nervous system (CNS) lymphoma Karnofsky Performance Status (KPS) >50% (Eastern Cooperative Oncology Group [ECOG] 0-2) The following laboratory values at screening, unless abnormalities are related to the lymphoma: Absolute neutrophil count (ANC) >1000 cells/dL; Platelets >50,000 cells/dL; Aspartate transaminase (AST) <3 x upper limit of normal (ULN); Alanine transaminase (ALT) <3 x ULN; Total bilirubin <2 x ULN; Creatinine level <150 µmol/L Toxic effects of previous therapy or surgery resolved to Grade 2 or better. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Women are neither breast feeding nor pregnant for the duration of the study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Male subject agrees to use an acceptable method of contraception for the duration of the study. Voluntary signed informed consent before performance of any study-related procedure not part of normal medical care. Patient with minimum life expectancy of 3 months. Exclusion Criteria: Any other type of lymphoma. Previous treatment with Velcade™. Anti-neoplastic or experimental or radiation therapy within 3 weeks before Day 1 of Cycle 1. Major surgery within 2 weeks before Day 1 of Cycle 1. Rituximab, alemtuzumab (Mabcampath®), or other unconjugated therapeutic antibody within 10 weeks before Day 1 of Cycle 1. Nitrosoureas within 6 weeks before Day 1 of Cycle 1. Radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin™), or tositumomab (Bexxar®) within 10 weeks before Day 1 of Cycle 1. Peripheral neuropathy or neuropathic pain of Grade 3 or worse. History of allergic reaction attributable to compounds containing boron or mannitol. Diagnosed or treated for a malignancy other than non-Hodgkin's lymphoma (NHL) within 5 years before Day 1 of Cycle 1, with the exception of complete resection of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy. Active systemic infection requiring treatment. Previously known HIV positive serology. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Concurrent treatment with another investigational agent. Adult patient under guardian.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bertrand Coiffier, MD
Organizational Affiliation
Hospices Civils de Lyon, Lyon, France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Vincent Ribrag, MD
Organizational Affiliation
Institut Gustave Roussy, Villejuif, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groupe d'Etude des Lymphomes de l'adulte
City
Mont-Godinne
Country
Belgium
Facility Name
Service d'Hématologie - Centre Hospitalier Lyon-Sud
City
Pierre-Bénite cedex
ZIP/Postal Code
69495
Country
France
Facility Name
Centre Henri Becquerel
City
Rouen
ZIP/Postal Code
76038
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
15613699
Citation
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 1;23(4):676-84. doi: 10.1200/JCO.2005.02.050. Epub 2004 Dec 21.
Results Reference
background
PubMed Identifier
15613697
Citation
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21.
Results Reference
background
Links:
URL
http://www.gela.org
Description
Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)

Learn more about this trial

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

We'll reach out to this number within 24 hrs